We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01933802
Recruitment Status : Completed
First Posted : September 2, 2013
Last Update Posted : March 19, 2018
Sponsor:
Information provided by (Responsible Party):
Tisch Multiple Sclerosis Research Center of New York

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The study is an open-label, phase I clinical trial designed to evaluate the safety and tolerability of intrathecal administration of autologous mesenchymal stem cell-derived neural progenitor cells (MSC-NP) in patients with progressive multiple sclerosis. Study participants will receive three intrathecal injections of culture-expanded autologous MSC-NPs at three month intervals.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Biological: intrathecal administration of autologous MSC-NP Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis
Study Start Date : April 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: autologous MSC-NP
intrathecal administration of autologous MSC-NP in three doses at three month intervals
 Biological: intrathecal administration of autologous MSC-NP
Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: 9 months ]
    The primary objective of the study is to assess the safety and tolerability of intrathecal therapy with autologous MSCNPs in MS. Number of participants with adverse events will be documented 1 day, 1 week, 1 month and 2 months post treatment for three treatments (followup for third treatment is 3 months instead of 2 months).

  2. Number of participants with adverse events . [ Time Frame: 30 months ]
    The co-primary objective will be to observe long term safety of the treatment 6 months and 30 months following the last treatment.


Secondary Outcome Measures :
  1. Preliminary evaluation of efficacy [ Time Frame: 9 months ]
    The secondary objective is to observe trends in efficacy over the course of the experimental treatment. Outcome measures include evoked potentials (baseline and 3 months post 3rd dose) ,quality of life questionnaire, EDSS, and MSFC (baseline, at the time of each dose, and 3 and 6 months after third dose), and MRI (baseline, 2 months after first dose, and 3 and 24 months after third dose).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of MS as defined by the McDonald criteria
  • Diagnosis of primary progressive or secondary progressive MS
  • Between the ages of 18-70 years
  • Significant disability shown by an Expanded Disability Status Score (EDSS) of 3.0 or greater that was not acquired within the last 12 months
  • Stable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months
  • Must agree to undergo MRIs at the time of enrollment, 2 months after the first treatment, and 27 months after the last treatment
  • Live in northern New Jersey, southern New York, or southwestern Connecticut during the study period, or patients must be able to arrange reliable travel accommodations to be present for every study visit if they live farther away.

Exclusion Criteria:

  • Pregnant or nursing mothers or any woman intending to become pregnant in the next three years
  • All patients will have pre-study liver function tests, PT/PPT, platelets, hematocrit, and renal function laboratory tests done. Only patients whose values are in the normal range as determined by the laboratory norms based on age and sex will be allowed to participate.
  • Use of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure
  • Any patients with a history of or with active malignancy
  • Use of steroids within three months of the study start date, as this would suggest a highly active disease state
  • History of cirrhosis due to increased risk of central nervous system (CNS) infection
  • Poorly controlled hypertension because of increased risk for stroke or CNS hemorrhage. Specifically, any patient with a systolic blood pressure value of ≥ 145 mm/Hg or a diastolic blood pressure value of ≥ 95 mm/Hg will be excluded from study participation.
  • History of thyroid disorders or other endocrine disorders because of hormone influence on cell growth
  • History of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection
  • Preexisting blood disease (such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia) due to invasive nature of bone-marrow aspiration
  • Previous or current history of a coagulation disorder
  • Any metal in the body, which is contraindicated for MRI studies
  • Allergy to any of the antibiotics used in this study, e.g. tobramycin, vancomycin, or gentamicin
  • Patients with alcohol or other substance abuse problems
  • Other major disease that, in the opinion of the Principal Investigator, would preclude participation in the study
  • Patients with HBV, HCV, syphilis, HIV-1, or HIV-2.
  • Any evidence of significant cognitive dysfunction based on a screening history and physical examination because it would preclude giving a truly informed consent
  • Patients who are enrolled in another clinical trial for MS treatment or who have received any study drug/biologics within the last 6 months
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01933802


Locations
Layout table for location information
United States, New York
Tisch MS Research Center of New York
New York, New York, United States, 10019
Sponsors and Collaborators
Tisch Multiple Sclerosis Research Center of New York
Investigators
Layout table for investigator information
Principal Investigator: Saud A Sadiq, MD Tisch MS Research Center of New York
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:

Other Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Tisch Multiple Sclerosis Research Center of New York
ClinicalTrials.gov Identifier: NCT01933802    
Other Study ID Numbers: TISCHMS-MSCNP-001
IND 13889 ( Other Identifier: FDA )
First Posted: September 2, 2013    Key Record Dates
Last Update Posted: March 19, 2018
Last Verified: March 2018
Keywords provided by Tisch Multiple Sclerosis Research Center of New York:
mesenchymal stem cells
neural progenitors
autologous
bone marrow
multiple sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
 Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases